Date: 2013-09-06
Type of information: Development agreement
Compound: MIV-210 (lagociclovir valactate)
Company: Medivir (Sweden) Daewoong Pharmaceutical (South Korea)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism: MIV-210 is a nucleoside analogue.
Disease: hepatitis B
Details: * On September 6, 2013, Medivir has announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical. Under the terms of this collaboration agreement Daewoong has been responsible for the R&D work. MIV-210 has a demonstrably competitive antiviral activity but, like other drugs of this class, does not completely eradicate HBV. The commercial environment for HBV drugs, with the current standard of care approaching generic status, requires a robust cure profile. To achieve this cure profile would require combination with other drugs with different and new mechanisms. “In light of the characteristics MIV-210 could offer for the treatment of Hepatitis B, we have together with our partner Daewoong decided to abandon the development activities with MIV-210”, said Maris Hartmanis, CEO, Medivir AB.
Medivir and Daewoong Pharmaceutical Co have announced their license agreement for this HBV polymerase inhibitor drug in March 2010.
Financial terms:
Latest news:
